The study is examining the effectiveness of its nano-medicine NBTXR3 in patients with soft tissue sarcoma, a cancer found in muscle and fatty areas.
Showing 25 of 5390
The £12mln fund-raise in November left the company tooled-up to develop its breakthrough erectile dysfunction
Cantor Fitzgerald has repeated a 'buy' rating on Redx Pharma after the company reported progress on the development of cancer treatments
The company said it has achieved healthy sales growth across its paper and technical fibre products divisions
The shares were issued at the same price they closed at on Tuesday, no mean feat for a company on the junior market
The company is partnering with F Lima, which supplies consumer brands to supermarkets and pharmacies.
Vectura said the integration of fellow drug maker Skyepharma following its merger is well advanced
"We are pleased to have carried the strong momentum from the first half of 2016 through to the end of the calendar year, continuing to make significant progress across all areas of the business,” said chief executive Doug Doerfler.
L&G upped its stake in the recent £4.1mln fundraising, and now holds a 3.5% stake in ImmuPharma
The online store will sell standard collagen products directly to end users in the research market
A study of more than 300,000 people spanning six countries showed Farxiga significantly cut the risk of death or heart failure in diabetes sufferers
ZS-9 is a treatment for hyperkalaemia – a condition where potassium levels in the blood are too high
Managed access programmes of the type overseen by Idis allow doctors to request unlicensed therapies for patients.
The year-long study over 50 sites in Germany, Sweden, Austria and Poland
Gross profits at Link rose by 35%, with South Africa especially strong, while Clinigen’s speciality pharma division got a boost from anti-viral drug Foscavir
The data, expected in the next month or so, will keep the biotech firm on track to take the first Affimer candidate into phase 1 studies, targeted for 2019
Per Rehné and Christina Wood have now officially joined the board
Results were ahead of market expectations and the group finished the year with a positive net cash position
The company is looking to complete at least one revenue-generating deal on the C4XD portfolio in the next 12 months
The firm is to develop benchmarks for an assay for three commonly tested genetic disorders.
The biopharma company said it has made progress on the development of several cancer treatments
The two parties would work together to develop a next-generation REX device
IPF causes a build-up of scar tissue, which damages the structure of the lung and affects normal uptake of oxygen into the blood.
ValiRx shares have gained today after Beaufort issued a 'speculative buy' rating and a target price of 6.0p
A formal sustained release sterile manufacturing licence will be granted by the Spanish authorities upon completion of final process validation